<DOC>
	<DOCNO>NCT00890981</DOCNO>
	<brief_summary>To evaluate combined effect denosumab treatment discontinuation cortical thickness distal radius High Resolution-Peripheral Quantitative Computed Tomography ( HR-pQCT ) . Participants randomize either denosumab placebo 20050179 ( NCT00293813 ) study complete study ( ie , attend end study visit ) include study . At least 12 month elapse since patient 's 20050179 end study visit .</brief_summary>
	<brief_title>A High-resolution Peripheral Quantitative Computed Tomography Study Postmenopausal Women Previously Treated With Denosumab</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Ambulatory , postmenopausal woman Randomized either denosumab placebo 20050179 ( NCT00293813 ) study complete study ( ie , attend end study visit ) At least 12 month elapse since end 20050179 study visit Provide sign informed consent Subjects fail receive dos denosumab ( SQ [ subcutaneous ] placebo ) 20050179 study Subjects randomize alendronate arm 20050179 study Subjects diagnose follow condition follow completion 20050179 study : Hyperthyroidism Hyperparathyroidism Malignancy within last 5 year ( except cervical carcinoma situ basal cell carcinoma ) Any condition require chronic ( great three month cumulative great 5 mg/day ) glucocorticoid therapy Other disease affect bone metabolism Selfreported alcohol drug abuse within previous 12 month Any disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply study procedure Received investigational product denosumab two year screen visit . Received &gt; 3 month ( equivalent ) osteoporosis treatment since complete 20050179 study . Current use follow osteoporosis agent : bisphosphonates , calcitonin , fluoride , parathyroid hormone analogue , selective estrogen receptor modulators , systemic oral transdermal estrogen ( except vaginal preparation estrogen cream acceptable ) , strontium tibolone . Currently enrol yet complete least 1 month since end investigational device drug trial ( ) ( Amgen trial 20080287 ) , subject receive investigational agent ( ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>